TriRx Pharmaceutical Services, LLC, a contract development, and manufacturing organization (CDMO), welcomed the UK Government’s recent announcement on England’s second Investment Zone, focused on Life Sciences in the Liverpool City Region.

TriRx Speke Ltd. is the first investor and is well-positioned to further advance its capabilities by adding upstream technologies to manufacture monoclonal antibodies to an existing large-scale biotech purification facility. The current facility has significant capacity to support the high-growth large-molecule pharmaceutical market. Monoclonal antibodies (mAbs) are a type of immunotherapy that work by blocking certain diseases from affecting healthy cells and are used to treat numerous types of diseases including cancers, arthritis, and skin conditions. The additional investment to augment the TriRx facility at Speke will foster economic growth, create high-value jobs, and complement the existing Speke Biopharmaceutical cluster in the region.

“We are delighted to be expanding our capability in this critical immunotherapy area, to become a worldwide center of technical excellence located in the UK in the monoclonal antibody development and manufacturing field to serve the human and animal pharmaceutical markets,” said Tim Tyson, Chairman and CEO of TriRx.